Cryopreserved Mesenchymal Stromal Cells Maintain Potency in a Retinal Ischemia/Reperfusion Injury Model: Toward an off-the-shelf Therapy

• DOI: 10.1038/srep26463
• Publication Date: 2016-05-24T06:44:49Z
• Authors: Oliver W. Gramlich; Anthony J. Burand; Alex J. Brown; Riley J. Deutsch; Markus H. Kuehn; James A. Ankrum
• Keywords: Viability assay; Cell therapy

Abstract The ability to use mesenchymal stromal cells (MSC) directly out of cryostorage would significantly reduce the logistics MSC therapy by allowing on-site therapeutic doses at hospitals and clinics. Such a paradigm be especially advantageous for treatment acute conditions such as stroke myocardial infarction, which are likely require within hours after ischemic onset. Recently, several reports have emerged that suggest viability potency damaged cryopreservation. Herein we examine effect cryopreservation on human viability, immunomodulatory potency, growth factor secretion performance in an ischemia/reperfusion injury model. Using modifications established methods developed retain >95% upon thawing, remain responsive inflammatory signals able suppress activated peripheral blood mononuclear cells. Most importantly, when injected into eyes mice 3 onset ischemia 2 reperfusion, cryopreserved performed well fresh rescue retinal ganglion Thus, our data suggests is maintained throughout process, their both vitro assays vivo